Escherichia coli Nissle 1917 (Mutaflor): New Insights into an Old Probiotic Bacterium
The DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.
Abstract
Probiotic bacteria are live microorganisms which contribute health benefits to their host. The numerous mechanisms of the probiotic-acting microorganisms include the induction of expression of certain cytokines and increasing the secretion of IgA and mucin. They activate lymphocytes and macrophages and inhibit the adhesion and invasion of epithelial cells. Escherichia coli Nissle 1917 (Mutaflor) is one of the most investigated probiotic bacteria. While the number of reports discussing the underlying mechanisms of Mutaflor has increased rapidly in recent years, novel clinical studies are missing. Here we provide an overview of the mechanisms of action and clinical studies related to Mutaflor. While most of the studies had positive outcomes, there are also a few in which Mutaflor did not perform to its expectations.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The Nissle 1917 strain of E. coli was isolated from a soldier during World War I who appeared resistant to an outbreak of dysentery, and has subsequently been applied as a probiotic treatment for gastrointestinal ailments including ulcerative colitis and Crohn's disease 83, 84.”
From Buried Treasure: Evolutionary Perspectives on Microbial Iron Piracy (2015) · cites this paper as [84]
Citations
Cites
Kruis, W., Frič, P., Pokrotnieks, J., Lukáš, M., Fixa, B., Kaščák, M., Kamm, M. A., Weismueller, J., Beglinger, C., Stolte, M., et al. (2004) · Gut · doi:10.1136/gut.2003.037747 · Cited by 1,285
Rembacken, B., Snelling, A., Hawkey, P., Chalmers, D., & Axon, A. (1999) · The Lancet · doi:10.1016/s0140-6736(98)06343-0 · Cited by 1,101
KRUIS, W., SCHÜTZ, E., FRIC, P., FIXA, B., JUDMAIER, G., & STOLTE, M. (1997) · Alimentary Pharmacology & Therapeutics · doi:10.1046/j.1365-2036.1997.00225.x · Cited by 775
Wehkamp, J., Harder, J., Wehkamp, K., Meissner, B. W.-V., Schlee, M., Enders, C., Sonnenborn, U., Nuding, S., Bengmark, S., Fellermann, K., et al. (2004) · Infection and Immunity · doi:10.1128/iai.72.10.5750-5758.2004 · Cited by 474
Zyrek, A. A., Cichon, C., Helms, S., Enders, C., Sonnenborn, U., & Schmidt, M. A. (2007) · Cellular Microbiology · doi:10.1111/j.1462-5822.2006.00836.x · Cited by 428
Analysis of the Genome Structure of the Nonpathogenic Probiotic Escherichia coli Strain Nissle 1917
Grozdanov, L., Raasch, C., Schulze, J., Sonnenborn, U., Gottschalk, G., Hacker, J., & Dobrindt, U. (2004) · Journal of Bacteriology · doi:10.1128/jb.186.16.5432-5441.2004 · Cited by 368
Clinical use of E. coli Nissle 1917 in inflammatory bowel disease
Schultz, M. (2008) · Inflammatory Bowel Diseases · doi:10.1002/ibd.20377 · Cited by 310
Engineered bacterial communication prevents Vibrio cholerae virulence in an infant mouse model
Duan, F., & March, J. C. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1001294107 · Cited by 247
Patzer, S. I., Baquero, M. R., Bravo, D., Moreno, F., & Hantke, K. (2003) · Microbiology · doi:10.1099/mic.0.26396-0 · Cited by 233
Altenhoefer, A., Oswald, S., Sonnenborn, U., Enders, C., Schulze, J., Hacker, J., & Oelschlaeger, T. A. (2004) · FEMS Immunology & Medical Microbiology · doi:10.1016/s0928-8244(03)00368-7 · Cited by 221
Cited by
Mutational signature in colorectal cancer caused by genotoxic pks+ E. coli
Pleguezuelos-Manzano, C., Puschhof, J., Rosendahl Huber, A., van Hoeck, A., Wood, H. M., Nomburg, J., Gurjao, C., Manders, F., Dalmasso, G., Stege, P. B., et al. (2020) · Nature · doi:10.1038/s41586-020-2080-8 · Cited by 1,208
Probiotics for the prevention of Clostridium difficile-associated diarrhea in adults and children
Goldenberg, J. Z., Ma, S. S., Saxton, J. D., Martzen, M. R., Vandvik, P. O., Thorlund, K., Guyatt, G. H., & Johnston, B. C. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006095.pub3 · Cited by 741
Probiotic Bacteria Reduce Salmonella Typhimurium Intestinal Colonization by Competing for Iron
Deriu, E., Liu, J. Z., Pezeshki, M., Edwards, R. A., Ochoa, R. J., Contreras, H., Libby, S. J., Fang, F. C., & Raffatellu, M. (2013) · Cell Host & Microbe · doi:10.1016/j.chom.2013.06.007 · Cited by 550
“coli Nissle, several studies have proposed that selective immune modulation may contribute to its activity(reviewed in (Behnsen et al., 2013; Jacobi and Malfertheiner, 2011), including the activation of γδ T cells (Guzy et al.”
BackgroundProbiotics for the prevention of Clostridium difficile-associated diarrhea in adults and children
Goldenberg, J. Z., Yap, C., Lytvyn, L., Lo, C. K.-F., Beardsley, J., Mertz, D., & Johnston, B. C. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006095.pub4 · Cited by 550
Microcins mediate competition among Enterobacteriaceae in the inflamed gut
Sassone-Corsi, M., Nuccio, S.-P., Liu, H., Hernandez, D., Vu, C. T., Takahashi, A. A., Edwards, R. A., & Raffatellu, M. (2016) · Nature · doi:10.1038/nature20557 · Cited by 549
Liévin-Le Moal, V., & Servin, A. L. (2014) · Clinical Microbiology Reviews · doi:10.1128/cmr.00080-13 · Cited by 354
“coli Nissle strain (261) was administered to mice with S.”
MethodCao, Z., Wang, X., Pang, Y., Cheng, S., & Liu, J. (2019) · Nature Communications · doi:10.1038/s41467-019-13727-9 · Cited by 337
Sassone-Corsi, M., & Raffatellu, M. (2015) · The Journal of Immunology · doi:10.4049/jimmunol.1403169 · Cited by 328
“coli Nissle is the active component of a probiotic preparation used for the treatment of both infectious diarrheal diseases and inflammatory bowel disease (26).”
BackgroundSonnenborn, U. (2016) · FEMS Microbiology Letters · doi:10.1093/femsle/fnw212 · Cited by 315
From yaks to yogurt: the history, development, and current use of probiotics
McFarland, L. V. (2015) · Clinical Infectious Diseases · doi:10.1093/cid/civ054 · Cited by 248
“Escherichia coli Nissle DSM6601 In 1917, Alfred Nissle isolated from healthy soldier during WWI Prevent salmonellosis and shigellosis Jacobi, 2011 [21]”
BackgroundPolymerization‐Mediated Multifunctionalization of Living Cells for Enhanced Cell‐Based Therapy
Pan, C., Li, J., Hou, W., Lin, S., Wang, L., Pang, Y., Wang, Y., & Liu, J. (2021) · Advanced Materials · doi:10.1002/adma.202007379 · Cited by 241
CRISPR-Cas-Based Antimicrobials: Design, Challenges, and Bacterial Mechanisms of Resistance
Mayorga-Ramos, A., Zúñiga-Miranda, J., Carrera-Pacheco, S. E., Barba-Ostria, C., & Guamán, L. P. (2023) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.2c00649 · Cited by 207
Yang, X., Yang, J., Ye, Z., Zhang, G., Nie, W., Cheng, H., Peng, M., Zhang, K., Liu, J., Zhang, Z., et al. (2022) · ACS Nano · doi:10.1021/acsnano.1c09681 · Cited by 194
Microcins in Enterobacteriaceae: Peptide Antimicrobials in the Eco-Active Intestinal Chemosphere
Baquero, F., Lanza, V. F., Baquero, M.-R., del Campo, R., & Bravo-Vázquez, D. A. (2019) · Frontiers in Microbiology · doi:10.3389/fmicb.2019.02261 · Cited by 171
“An oral preparation of the strain E. coli Nissle, 1917 (Jacobi and Malfertheiner, 2011) has been used for over 100 years as a useful probiotic preparation for therapy of bacterial intestinal diseases, starting during the First World War (Nissle, 1916, 1918; Henker et al., 2007; Sonnenborn and…”
MethodThe microbial ecology of Escherichia coli in the vertebrate gut
Foster-Nyarko, E., & Pallen, M. J. (2022) · FEMS Microbiology Reviews · doi:10.1093/femsre/fuac008 · Cited by 180
“Escherichia coli Nissle 1917 (also known as Mutaflor) is one of the most extensively researched probiotic strains globally (Jacobi and Malfertheiner 2011).”
Insights from 100 years of research with probiotic E. coli
Wassenaar, T. M. (2016) · European Journal of Microbiology and Immunology · doi:10.1556/1886.2016.00029 · Cited by 145
“Some citations state that the lucky soldier remained free from “diarrhea” [58] or “shigellosis” [59] while yet others mention his resistance was against typhoid fever.”
BackgroundHigh‐efficiency delivery of CRISPR‐Cas9 by engineered probiotics enables precise microbiome editing
Neil, K., Allard, N., Roy, P., Grenier, F., Menéndez, A., Burrus, V., & Rodrigue, S. (2021) · Molecular Systems Biology · doi:10.15252/msb.202110335 · Cited by 162
“Because of a long history of clinical use (Jacobi & Malfertheiner, 2011) and the availability of efficient genetic manipulation tools, we selected E . coli Nissle 1917 (EcN) as our initial testbed.”
Secher, T., Kassem, S., Benamar, M., Bernard, I., Boury, M., Barreau, F., Oswald, E., & Saoudi, A. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01096 · Cited by 148
“ECN is one of the most investigated probiotic bacteria (41).”
BackgroundThe manifold roles of microbial ribosomal peptide–based natural products in physiology and ecology
Li, Y., & Rebuffat, S. (2019) · Journal of Biological Chemistry · doi:10.1074/jbc.rev119.006545 · Cited by 157
“Today it is one of the most investigated bacterial strains, but despite its commercialization and numerous applications, the mechanisms underlining its positive properties to regulate intestinal disorders of infectious or inflammatory origin remain still obscure (106).”
BackgroundThe Intestinal Microbiota: Impacts of Antibiotics Therapy, Colonization Resistance, and Diseases
Shah, T., Baloch, Z., Shah, Z., Cui, X., & Xia, X. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22126597 · Cited by 106
From cells to muropeptide structures in 24 h: Peptidoglycan mapping by UPLC-MS
Kühner, D., Stahl, M., Demircioglu, D. D., & Bertsche, U. (2014) · Scientific Reports · doi:10.1038/srep07494 · Cited by 122
Hu, R., Lin, H., Li, J., Zhao, Y., Wang, M., Sun, X., Min, Y., Gao, Y., & Yang, M. (2020) · BMC Microbiology · doi:10.1186/s12866-020-01953-x · Cited by 123
Buried Treasure: Evolutionary Perspectives on Microbial Iron Piracy
Barber, M. F., & Elde, N. C. (2015) · Trends in Genetics · doi:10.1016/j.tig.2015.09.001 · Cited by 118
“coliwas isolated from a soldier during World War I who appeared resistant to an outbreak of dysentery, and has subsequently been applied as a probiotic treatment for gastrointestinal ailments including ulcerative colitis and Crohn's disease [83,84].”
BackgroundServin, A. L. (2014) · Clinical Microbiology Reviews · doi:10.1128/cmr.00036-14 · Cited by 143
“coli strain with diverse activities (248) is intriguing since its promotion of gut homeostasis activity in response to mucosal injury cannot be dissociated from the presence of the pks island (249).”
BackgroundProteomic analysis of outer membrane vesicles from the probiotic strain Escherichia coli Nissle 1917
Aguilera, L., Toloza, L., Gíménez, R., Odena, M. A., de Oliveira, E., Aguilar, J., Badía, J., & Baldomà, L. (2013) · PROTEOMICS · doi:10.1002/pmic.201300328 · Cited by 112
“EcN increases secretion of IgA and mucin, modifies cytokine balance in favor of anti-inflammatory cytokines and promotes upregulation and redistribution of tight junction proteins [1].”
BackgroundMatušková, Z., Anzenbacherová, E., Večeřa, R., Tlaskalová‐Hogenová, H., Kolář, M., & Anzenbacher, P. (2014) · PLoS ONE · doi:10.1371/journal.pone.0087150 · Cited by 97
“It may be speculated that in response to lowered levels of this cytokine in presence of EcN (for a review, see [30]), the expression of the Oatp2B1 transporter may be in turn higher leading to better”
BackgroundComplete genome sequence of the Gram-negative probiotic Escherichia coli strain Nissle 1917
Reister, M., Hoffmeier, K., Krezdorn, N., Rotter, B., Liang, C., Rund, S. A., Dandekar, T., Sonnenborn, U., & Oelschlaeger, T. A. (2014) · Journal of Biotechnology · doi:10.1016/j.jbiotec.2014.07.442 · Cited by 113
Forty Years of Oxalobacter formigenes, a Gutsy Oxalate-Degrading Specialist
Daniel, S. L., Moradi, L., Paiste, H., Wood, K. D., Assimos, D. G., Holmes, R. P., Nazzal, L., Hatch, M., & Knight, J. (2021) · Applied and Environmental Microbiology · doi:10.1128/aem.00544-21 · Cited by 88
Whelan, R. A., Rausch, S., Ebner, F., Günzel, D., Richter, J. F., Hering, N. A., Schulzke, J.-D., Kühl, A. A., Keles, A., Janczyk, P., et al. (2014) · Molecular Therapy · doi:10.1038/mt.2014.125 · Cited by 77
Dopamine Polymerization-Mediated Surface Functionalization toward Advanced Bacterial Therapeutics
Wang, L., & Liu, J. (2024) · Accounts of Chemical Research · doi:10.1021/acs.accounts.3c00798 · Cited by 69
Lan, Y.-J., Tan, S., Cheng, S., Ting, W., Xue, C., Lin, T.-H., Cai, M.-Z., Chen, P., & Ng, I. (2021) · Biochemical Engineering Journal · doi:10.1016/j.bej.2021.107952 · Cited by 69
Manzhalii, E., Hornuss, D., & Stremmel, W. (2016) · World Journal of Gastroenterology · doi:10.3748/wjg.v22.i23.5415 · Cited by 59
Li, J., Sun, M., Liu, L., Yang, W., Sun, A., Yu, J., Liu, D., Zhao, W., Cheng, M., He, Z., et al. (2023) · Nano Letters · doi:10.1021/acs.nanolett.3c02408 · Cited by 64
Novel strategies for modulating the gut microbiome for cancer therapy
Cho, Y. S., Han, K., Xu, J., & Moon, J. J. (2024) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2024.115332 · Cited by 65
“Harimoto et al . engineered Escherichia coli Nissle 1917 (EcN), a widely studied probiotic bacterium [90], with a programmable capsular polysaccharide gene circuit.”
Bergström, A., Kristensen, M. B., Bahl, M. I., Metzdorff, S. B., Fink, L. N., Frøkiær, H., & Licht, T. R. (2012) · BMC Research Notes · doi:10.1186/1756-0500-5-402 · Cited by 57
“coli Nissle (Ec) [20,21], and from germ free (GF) mice [15,22].”
BackgroundOrtuño‐Sahagún, D., Márquez-Aguirre, A. L., Quintero-Fabián, S., López-Roa, R. I., & Rojas-Mayorquín, A. E. (2012) · PPAR Research · doi:10.1155/2012/318613 · Cited by 65
“At present, this bacterium is contained in a probiotic drug called Mutaflor, whose efficacy against inflammatory states in lower gastrointestinal tract has been demonstrated in numerous trials (reviewed in [176]).”
BackgroundLi, P., Zhu, L., Song, C., Wu, M., Zhu, X., He, S., Hu, B., Chen, Z., Liu, Z., Luo, B., et al. (2025) · ACS Nano · doi:10.1021/acsnano.5c00574 · Cited by 56
Bernardeau, M., & Vernoux, J. (2013) · Clinical Microbiology and Infection · doi:10.1111/1469-0691.12130 · Cited by 58
Mohsin, M., Guenther, S., Schierack, P., Tedin, K., & Wieler, L. H. (2014) · International Journal of Medical Microbiology · doi:10.1016/j.ijmm.2014.10.003 · Cited by 55
Rebuffat, S. (2022) · Natural Product Reports · doi:10.1039/d1np00052g · Cited by 51
Effendi, S. S. W., & Ng, I. (2022) · Critical Reviews in Microbiology · doi:10.1080/1040841x.2022.2109405 · Cited by 49
“EcN has been registered for a patent in 1917 and marketed under Mutaflor(R) trademark as an intestinal resistance since 1932 (Jacobi and Malfertheiner 2011; Sonnenborn 2016).”
BackgroundFang, T., & Liu, S. (2023) · Small · doi:10.1002/smll.202308146 · Cited by 54
Hu, S., Zhao, L., Hu, L., Xi, X., Zhang, Y., Wang, Y., Chen, J., Chen, J., & Kang, Z. (2022) · Enzyme and Microbial Technology · doi:10.1016/j.enzmictec.2022.110038 · Cited by 43
Harnessing the potential of probiotics in the treatment of alcoholic liver disorders
Mishra, G., Singh, P. N. D., Molla, M., Yimer, Y. S., Dinda, S. C., Chandra, P., Singh, B. K., Dagnew, S. B., Assefa, A. N., & Ewunetie, A. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1212742 · Cited by 43
Fiege, K., Querebillo, C. J., Hildebrandt, P., & Frankenberg‐Dinkel, N. (2018) · Biochemistry · doi:10.1021/acs.biochem.8b00242 · Cited by 47
Sitkin, S. I., Vakhitov, T., & Demyanova, E. V. (2018) · Almanac of Clinical Medicine · doi:10.18786/2072-0505-2018-46-5-396-425 · Cited by 48
Jacobi, C. A., Grundler, S., Hsieh, C., Frick, J.-S., Adam, P., Lamprecht, G., Autenrieth, I. B., Gregor, M., & Malfertheiner, P. (2012) · Gut Pathogens · doi:10.1186/1757-4749-4-8 · Cited by 43
“coli Nissle is exerting its beneficial effects are still not completely understood [23].”
BackgroundSelf-citationToloza, L., Gíménez, R., Fábrega, M.-J., Álvarez-Villagómez, C. S., Aguilera, L., Cañas, M. A., Martín-Venegas, R., Badía, J., & Baldomà, L. (2015) · BMC Microbiology · doi:10.1186/s12866-015-0591-5 · Cited by 37
“is a Gram-negative probiotic used in the treatment of intestinal disorders, especially inflammatory bowel diseases [1–3].”
BackgroundYim, J., Cho, S. W., Kim, B., Park, S., Han, Y. H., & Seo, S. W. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21082666 · Cited by 33
“For instance, it is the probiotic used in Mutaflor, which is medically effective in treating chronic constipation and Crohn’s disease, a type of autoimmune disease [18].”
BackgroundA Review of Research Conducted with Probiotic E. coli Marketed as Symbioflor
Beimfohr, C. (2016) · International Journal of Bacteriology · doi:10.1155/2016/3535621 · Cited by 30
“The properties of that strain have been reviewed elsewhere [1], but here all peer-reviewed publications dealing”
BackgroundSécher, T., Maillet, I., Mackowiak, C., Bérichel, J. L., Philippeau, A., Panek, C., Boury, M., Oswald, É., Saoudi, A., Erard, F., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-29689-9 · Cited by 31
“The beneficial effects of ECN has been demonstrated before in intestinal inflammatory disorders, especially in ulcerative colitis 43 .”
BackgroundLi, N., Wu, M., Wang, L., Tang, M., Xin, H., & Deng, K. (2024) · Membranes · doi:10.3390/membranes14060135 · Cited by 24
Defining microbiota for developing new probiotics
Collado, M. C., Bäuerl, C., & Pérez‐Martínez, G. (2012) · Microbial Ecology in Health and Disease · doi:10.3402/mehd.v23i0.18579 · Cited by 27
“coli probiotic strain Nissle 1917 has been found to reduce the number and incidence of infections, to stimulate specific humoral and cellular responses, and to induce the non-specific natural immunity in infants (34, 35).”
BackgroundWan, M. L. Y., Chen, Z., Shah, N. P., & El-Nezami, H. S. (2018) · Journal of Food Science · doi:10.1111/1750-3841.14168 · Cited by 22
Geervliet, M., de Vries, H., Jansen, C. A., Rutten, V. P. M. G., van Hees, H. M. J., Wen, C., Skovgaard, K., Antonello, G., Savelkoul, H. F. J., Smidt, H., et al. (2022) · Frontiers in Microbiology · doi:10.3389/fmicb.2022.842437 · Cited by 24
Olivo-Martínez, Y., Martínez-Ruiz, S., Cordero, C., Badía, J., & Baldomà, L. (2024) · Nutrients · doi:10.3390/nu16162719 · Cited by 21
Metabolic engineering of the probiotic Escherichia coli Nissle 1917 for lacto-N-triose II production
Hu, M., & Zhang, T. (2024) · Food Bioscience · doi:10.1016/j.fbio.2024.103959 · Cited by 20
Boubezari, M. T., Idoui, T., Hammami, R., Fernandez, B., Gomaa, A. I., & Fliss, I. (2018) · Archives of Microbiology · doi:10.1007/s00203-018-1482-6 · Cited by 20
“Among the Gram-negative bacteria with probiotic properties, E. coli strain Nissle 1917 is probably the most intensively investigated bacterial strain today (Jacobi and Malfertheiner 2011).”
Cheng, S., Lin, T.-H., & Chen, P. (2022) · Journal of Agricultural and Food Chemistry · doi:10.1021/acs.jafc.2c04614 · Cited by 19
Gelfat, I., Aqeel, Y., Tremblay, J. M., Jaskiewicz, J. J., Shrestha, A., Lee, J. N., Hu, S., Qian, X., Magoun, L., Sheoran, A. S., et al. (2022) · PLoS Pathogens · doi:10.1371/journal.ppat.1010713 · Cited by 19
Cao, Z., Wang, L., Liu, R., Lin, S., Wu, F., & Liu, J. (2022) · Materials Today Bio · doi:10.1016/j.mtbio.2022.100311 · Cited by 23
“As a proof-of-concept study, FAST is transformed into a well-known probiotic bacterium, Escherichia coli Nissle 1917 (EcN) [46,47], to prepare living bacterial probes (termed as EcN-FAST, Fig.”
MethodMa, Y., Fu, W., Hong, B., Wang, X., Jiang, S., & Wang, J. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241411688 · Cited by 17
“The good probiotic activity of EcN in humans and animals has been reported in several studies [12,13], and EcN has been proven to be very effective in relieving ulcerative colitis [14].”
BackgroundGenetic heterogeneity of engineered Escherichia coli Nissle 1917 strains during scale-up simulation
Munkler, L. P., Mohamed, E. T., Vazquez-Uribe, R., Nissen, V. V., Rugbjerg, P., Worberg, A., Woodley, J. M., Feist, A. M., & Sommer, M. O. A. (2024) · Metabolic Engineering · doi:10.1016/j.ymben.2024.08.001 · Cited by 18
Janečková, L., Kostovcikova, K., Švec, J., Šťastná, M., Strnad, H., Kolář, M., Hudcovic, T., Stančíková, J., Turečková, J., Dibus, N., et al. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20071581 · Cited by 18
“Additionally, the strain possibly exerts immune-response-related function(s) by either suppressing inflammation or enhancing the epithelial defense and/or barrier functions [77,78].”
BackgroundNejati, F., & Oelschlaeger, T. A. (2015) · Applied food biotechnology · doi:10.22037/afb.v3i1.10350 · Cited by 15
“However, probiotic characteristics have been reported for other food-derived lactobacilli [2,3], other members of lactic acid bacteria (LAB), such as enterococci and lactococci [4,5], and non-LAB, such as Escherichia coli [6].”
BackgroundExpectations for employing Escherichia coli Nissle 1917 in food science and nutrition
Hu, M., Zhang, T., Miao, M., Li, K., Luan, Q., & Sun, G. (2024) · Critical Reviews in Food Science and Nutrition · doi:10.1080/10408398.2023.2301416 · Cited by 14
“Mutaflor was used to treat gastrointestinal disorders, including diarrhea, and became a popular probiotic in Germany (Jacobi and Malfertheiner 2011).”
Schultz, M., & Burton, J. P. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-804024-9.00005-7 · Cited by 12
Heterologous expression and antimicrobial potential of class II bacteriocins
Rosenkilde, C. E. H., Lützhøft, D. O., Vazquez-Uribe, R., & Sommer, M. O. A. (2024) · Gut Microbes · doi:10.1080/19490976.2024.2369338 · Cited by 10
Lin, T.-H., Cheng, S., Lin, Y.-F., & Chen, P. (2024) · Journal of Agricultural and Food Chemistry · doi:10.1021/acs.jafc.4c01075 · Cited by 10
Darwish, M. S., Abou-Zeid, N. A., Khojah, E., Aljumayi, H., Alshehry, G. A., Algarni, E. H. A., & El-Awady, A. A. (2022) · Foods · doi:10.3390/foods11111663 · Cited by 11
“EcN has been improved as a probiotic product under the trademark name Mutaflor, and this has been widely used in Europe to treat infectious diarrhea and intestinal inflammation [7].”
BackgroundReevaluating the hype: four bacterial metabolites under scrutiny
Fröhlich, E. E., Mayerhofer, R., & Holzer, P. D. (2014) · European Journal of Microbiology and Immunology · doi:10.1556/eujmi-d-14-00030 · Cited by 9
“coli Nissle 1917 probiotic Mutafl or® in 1917 [178], or the Austrian researcher Friedrich Petuely, who in 1960 fi led a patent for the discovery of lactulose as “bifi do factor,” a prebiotic specifi cally enhancing growth of Bifi dobacteria strains [179], would be very content.”
BackgroundIdentification of a gene cluster for D-tagatose utilization in Escherichia coli B2 phylogroup
Ha, J., Kim, D. H., Yeom, J., Kim, Y.-S., Yoo, S. M., & Yoon, S. H. (2022) · iScience · doi:10.1016/j.isci.2022.105655 · Cited by 7
“coli strain Nissle 1917 (EcN), a B2 strain, has strong antagonistic activity against entero-pathogens, possesses immunomodulatory properties, and has been widely used for IBD treatment.(20,21) The metabolic potential of EcN is similar to that of uropathogenic B2 strain CFT073.”
BackgroundCömertpay, B., & Göv, E. (2025) · Journal of Clinical and Experimental Hepatology · doi:10.1016/j.jceh.2025.102552 · Cited by 6
Ting, W., Nishikawa, S., Yu, W.-C., He, M.-J., Chen, H.-C., Fujishima, K., Sung, Y.-J., Wang, K., Ng, I., & Wang, P. (2024) · ACS Sustainable Chemistry & Engineering · doi:10.1021/acssuschemeng.4c03510 · Cited by 6
Engineering bacterial-based biohybrid microrobots for magnetic torque-driven control
Regazzoni, L., Totter, E., Menghini, S., Oberhuber, I., Li, F., Forbrigger, C., Poc, P., Wang, X., Schirmer, C., Wagner, P., et al. (2025) · Cell Reports Physical Science · doi:10.1016/j.xcrp.2025.102909 · Cited by 7
Current and emerging approaches to manage chronic inflammatory gut disorders
Green, K. M., Shin, S., Jha, R. K., & Kumar, A. (2026) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2026.1762119 · Cited by 5
Redweik, G. A. J., & Xue, D. (2024) · PubMed Central · doi:10.17912/micropub.biology.001366 · Cited by 3
Cellular membrane protein MipA from E.coli Nissle 1917 protects against Salmonella infection
Xiang, Y., Peng, H., Li, Y., Wen, H., Li, N., Liu, X., Yuan, G., Shi, Y., & Huang, S. (2026) · The ISME Journal · doi:10.1093/ismejo/wrag054 · Cited by 3
Hung, J. J.-C., Tsai, T. P., & Lan, E. I. (2026) · Fermentation · doi:10.3390/fermentation12060265 · Cited by 4
Levin, R. (2017) · Wiley eBooks · doi:10.1002/9781119214137.ch2 · Cited by 3
From cells to muropeptide structures in 24 h: Peptidoglycan mapping by UPLC-MS
Bertsche, U., Kühner, D., Stahl, M., Demircioğlu, D. D., & Bertsche, U. (2014) · Protocol Exchange · doi:10.1038/protex.2014.055 · Cited by 3
Zhang, Z., Zheng, L., Zhao, W., Li, Y., Jiao, S., Jin, M., Wu, Y., Zhang, S., Ni, B. J., Chang, Z., et al. (2025) · Food Science and Human Wellness · doi:10.26599/fshw.2025.9250773 · Cited by 2
Deep characterization of Escherichia coli in a cohort of mothers and their infants
de Muinck, & Jacques, É. (2013) · Cited by 2
Park, K., Kim, Y.-S., Kim, D., Oh, S.-S., Koo, T. J., Yoo, S. M., & Yoon, S. H. (2025) · Microbial Cell Factories · doi:10.1186/s12934-025-02771-4 · Cited by 1
Metabolic host-microbe crosstalk in stabilization of epithelial HIF
Dowdell, A. S., Roer, R. L., Bhagavatula, G., Cartwright, I. M., Cohen, R. H., Countess, J. A., Koch, S. D., Lee, J. S., Liu, L., Steiner, C. A., et al. (2026) · Microbiome · doi:10.1186/s40168-026-02431-8 · Cited by 1
“To this end, we examined the ability of Escherichia coli to stabilize HIF-1α using commensal strains isolated from either human ( E. coli Nissle, EcN) or mouse (GDAR2-2) microbiota [23, 50].”
Vandenberghe, L. P. D. S., Valladares-Diestra, K. K., de Mello, A. F. M., de Oliveira, P. Z., de Mattos, P. B. G., de Assis, I. C., & Soccol, C. R. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-13966-6.00002-6 · Cited by 1
Kurtz, C. B., & Calvo, M. S. (2024) · Nutrition and Dietary Supplements · doi:10.2147/nds.s481755 · Cited by 1
“24 The products of these genes have been associated with genotoxicity, 25–27 and the entire gene cluster encoding these genes may be removed to improve the safety of the base strain.”
Zhang, Z., Zheng, L., Li, Y., Jiao, S., Wu, Y., Jin, M., Zhang, S., Gao, H., Chang, Z., Jiang, D., et al. (2024) · Research Square · doi:10.21203/rs.3.rs-3842060/v1 · Cited by 1
Maturana, L. T. (2014) · Dipòsit Digital de la Universitat de Barcelona (Universitat de Barcelona)
The impact of host-microbe interactions on murine colonic secretomotor function
Lomasney, K. W. (2014) · Cork Open Research Archive (University College Cork, Ireland)
E. coli´s fight against TYROnny: Designing a bacterial strain to tackle tyrosinemia type 1
Lücke, J., & Huber, S. (2023) · Journal of Hepatology · doi:10.1016/j.jhep.2023.11.010
Zhang, L., Yang, J., Shi, Q., Chu, Y., Cao, J., Shang, C., Zhou, C., & Ma, L. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1684234
Özduran, E. (2023) · Dspace Repository (Marmara Üniversitesi) · Cited by 1
Cañas, M. A. (2017) · Dipòsit Digital de la Universitat de Barcelona (Universitat de Barcelona) · Cited by 1
Rôle de l'îlot génomique pks dans la synthèse des sidérophores-microcines chez Escherichia coli
Massip, C. (2019) · theses.fr (ABES) · doi:10.70675/79fd3cdcz6be0z491ez95c5zf2b155b65e97
Directed Evolution of an Escherichia coli Secretor Strain Using the Curli Pathway
Kan, A., Emani, S. S., & Joshi, N. S. (2026) · ACS Synthetic Biology · doi:10.1021/acssynbio.6c00050
Engineered Calprotectin-Responsive Probiotics for Inflammatory Bowel Disease Treatment
Yang, F., He, L., Lin, X., Huang, X., Hu, Y., Chen, M., Wu, Z., Xi, J., Li, M., Li, M., et al. (2026) · ACS Synthetic Biology · doi:10.1021/acssynbio.6c00347
Habib, A. G. K., Fahmy, N. A., Lamichhane, B., & Helmy, Y. A. (2026) · Antibiotics · doi:10.3390/antibiotics15111096
Metadata
- Authors
- Jacobi, C. A., & Malfertheiner, P.
- Affiliations
- Klinikum Magdeburg (DE)
- Venue
- Digestive Diseases
- Publisher
- S. Karger AG
- Published
- 2011
- Volume
- 29
- Issue
- 6
- Pages
- 600-607
- ISSN
- 0257-2753 (ISSN-L)
- 1421-9875
- OpenAlex
- W1980621284
- Cited by
- 95
- References
- 44
- Citations by year
- 2026: 6 · 2025: 6 · 2024: 13 · 2023: 7 · 2022: 10 · 2021: 6 · 2020: 3 · 2019: 5 · 2018: 5 · 2017: 4 · 2016: 5 · 2015: 5 · 2014: 11 · 2013: 5 · 2012: 4
- FWCI
- 0.87
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.karger.com/Services/SiteLicenses (vor)
- www.karger.com/Services/SiteLicenses (tdm)
- Locations
- Digestive Diseases (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Agricultural and Biological Sciences › Food Science › Probiotics and Fermented Foods
- Health Sciences › Medicine › Gastroenterology › Gastrointestinal motility and disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Keywords
- Escherichia coli Nissle 1917, probiotics, mechanism of action, clinical trials, cytokine induction, IgA secretion, mucin secretion, immune activation, epithelial cell adhesion, clinical outcomes
- MeSH terms
- Clinical Trials as Topic, Escherichia coli, Humans, Probiotics
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.